471820 — Cellromax Science Co Balance Sheet
0.000.00%
- KR₩61bn
- KR₩49bn
- KR₩22bn
- 73
- 53
- 26
- 50
Annual balance sheet for Cellromax Science Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 5,148 | 7,044 | 11,800 | 22,732 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 1,675 | 621 | 602 | 641 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 12,348 | 13,244 | 17,120 | 30,878 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 5,395 | 5,180 | 5,533 | 3,661 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | 23,994 | 28,530 | 32,827 | 49,100 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 2,796 | 2,610 | 2,353 | 3,154 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Funded Status | ||||
| Total Liabilities | 2,976 | 2,765 | 2,713 | 4,579 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 21,018 | 25,765 | 30,115 | 44,522 |
| Total Liabilities & Shareholders' Equity | 23,994 | 28,530 | 32,827 | 49,100 |
| Total Common Shares Outstanding |